This is the first installment of a series dedicated to the molecular biology of unusual types of cancers called hyperprogressive disease that are colloquially referred to as “turbo cancers” (not a term used in medicine). In this episode, we provide the first ever published evidence of how IgG4 antibodies can play a role (in conjunction with other molecular events) in the development of turbo cancers.

What we cover:
*Turbo cancers exist in medicine but are called hyperprogressive disease
*Turbo cancers appear to require 3 elements in the same environment:
*cancer presence,
*high IgG4 levels and
*high glutathione levels
*IgG4 immune checkpoint inhibitors used in cancer treatment
*Hyperprogressive disease (turbo cancers) first described after the use of immune checkpoint inhibitors that were IgG4
*Molecular understanding of how it happens only emerged in the last 5 years
*Turbo cancers are still emerging knowledge as only a handful science papers published
*2019 study of turbo cancer patients shows unique immune cell behaviour in cancers
*2019 study of turbo cancers in mice provide genetic background predisposition


Location: Calgary, Alberta


Described content:
https://aacrjournals.org/clincancerre...


__________________________________________________________________
Dr. Raszek Credentials: https://merogenomics.ca/en/about/
____________________________________________________________________

Please stay in touch with us on other social media channels:

Twitter:   / merogenomics  
Facebook:   / merogenomics  
Blog: https://merogenomics.ca/blog/

Previously Microsoft was providing inappropriate warning about our newsletter sign up. If this happens again, there is an alternative option.

Original Newsletter sign up (safe!): https://share.ebforms.com/53718243485...
Alternate Newsletter sign up: http://eepurl.com/hesNGf

Instagram:   / merogenomics  
Patreon:   / merogenomics